All In Biotech

Drug Trial Radar · NCT04937166

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

25

Actual

Start

Jan 13, 2022

Primary completion

Apr 23, 2025

Study completion Oct 24, 2025

Sponsor

Lead sponsor
Kahr MedicalIndustry
Sponsor type
Industry
First posted
Jun 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) profile of DSP107 when administered in combination with azacitidine (AZA). Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of DSP107 when administered in combination with AZA and venetoclax (VEN).

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia

Interventions

  • DSP107Biological

    DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

  • AzacitidineDrug

    Azacitidine is an analog of the pyrimidine nucleoside cytidine.

  • VenetoclaxDrug

    Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: Duration of the study, estimated to be 12 months
  2. Dose Limiting Toxicities (DLT)Time frame: At the end of Treatment Cycle 2 (within 2 months of treatment initiation)
  3. Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)Time frame: Within 6 months of treatment initiation

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • The University of Texas MD Anderson Cancer Center, Department of Leukemia

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.